ArticleQuantitative imaging in medicine and surgery2025
Pancreatic extracellular volume fraction based on dual-energy computed tomography iodine maps: association with diabetes.
Article in Quantitative imaging in medicine and surgery, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Pancreatic fibrosis is closely related to blood glucose levels in diabetes, and pancreatic extracellular volume fraction (fECV) can quantify pancreatic fibrosis. The aim of this study was to investigate the correlation between pancreatic fECV measured by dual-energy computed tomography (DECT) iodine maps and hemoglobin A1c (HbA1c), and the feasibility of fECV in evaluating the progression of diabetes. Methods: This retrospective cross-sectional study included 213 patients who underwent abdominal contrast-enhanced DECT examinations; they were divided into two groups: non-diabetes (Group ND) and diabetes (Group D). Group ND included normal blood glucose (Group ND_N) and pre-diabetes (Group ND_PD). Group D included good blood glucose control (Group D_C) and poor blood glucose control (Group D_NC). HbA1c data were collected through electronic medical records. Pancreatic fECV was derived from DECT equilibrium phase iodine maps. Correlations between pancreatic fECV and HbA1c and comparisons of fECV among different groups were evaluated with Spearman's correlation and analysis of variance (ANOVA). Logistic regression analysis was conducted to investigate the association between pancreatic fECV and diabetes. Diagnostic value of fECV was assessed by receiver operating characteristic (ROC) curve. Results: HbA1c was positively correlated with fECV (r Conclusions: Pancreatic fECV is positively correlated with HbA1c, the independent indicator to assess the progression of diabetes, and could indirectly reflect pathophysiological changes of pancreas with diabetes and indicate progression of diabetes from imaging.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.